183 related articles for article (PubMed ID: 21486448)
1. The predictive significance of CD20 expression in B-cell lymphomas.
Prevodnik VK; Lavrenčak J; Horvat M; Novakovič BJ
Diagn Pathol; 2011 Apr; 6():33. PubMed ID: 21486448
[TBL] [Abstract][Full Text] [Related]
2. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
3. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical patterns of follicular dendritic cell meshwork and Ki-67 in small B-cell lymphomas].
Shi YF; Li XH
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):222-6. PubMed ID: 23928527
[TBL] [Abstract][Full Text] [Related]
5. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.
Starostka D; Kriegova E; Kudelka M; Mikula P; Zehnalova S; Radvansky M; Papajik T; Kolacek D; Chasakova K; Talianova H
Cytometry B Clin Cytom; 2018 Jul; 94(4):576-587. PubMed ID: 29220870
[TBL] [Abstract][Full Text] [Related]
7. [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
Suková V; Klabusay M; Coupek P; Brychtová Y; Doubek M; Mayer J
Cas Lek Cesk; 2006; 145(9):712-6; discussion 716-7. PubMed ID: 17091727
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma.
Espasa A; Tapia G; Vergara S; Raya M; Juncà J; Sorigue M
Scand J Clin Lab Invest; 2021 Sep; 81(5):413-417. PubMed ID: 34057378
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
10. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
11. [Expression of B cell-specific activator protein in lymphomas].
Li D; Li GD; Liu WP; Li FY; Zhang WY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):345-7. PubMed ID: 16185503
[TBL] [Abstract][Full Text] [Related]
12. Ocular adnexal lymphoproliferative disease: a series of 73 cases.
McKelvie PA; McNab A; Francis IC; Fox R; O'Day J
Clin Exp Ophthalmol; 2001 Dec; 29(6):387-93. PubMed ID: 11778809
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
15. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
16. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.
Morice WG; Kurtin PJ; Hodnefield JM; Shanafelt TD; Hoyer JD; Remstein ED; Hanson CA
Mayo Clin Proc; 2008 Jul; 83(7):776-85. PubMed ID: 18613994
[TBL] [Abstract][Full Text] [Related]
19. Immunofluorescent labeling of CD20 tumor marker with quantum dots for rapid and quantitative detection of diffuse large B-cell non-Hodgkin's lymphoma.
Shariatifar H; Hakhamaneshi MS; Abolhasani M; Ahmadi FH; Roshani D; Nikkhoo B; Abdi M; Ahmadvand D
J Cell Biochem; 2019 Mar; 120(3):4564-4572. PubMed ID: 30302797
[TBL] [Abstract][Full Text] [Related]
20. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
